Ftse Mib
33.736,40
-0,03%
DAX
17.896,50
-0,14%
S&P 500
5.064,20
0,91%
NASDAQ
15.840,96
1,51%
Bitcoin
59.794,69
1,14%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aquestive Therapeutics Inc (AQST) Aquestive Therapeutics Inc (AQST) Notizie

Aquestive Therapeutics Inc

AQST
3,28
-0,085 (-2,53%)
03 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
29/4/202413:00GLOBEAquestive Therapeutics Receives U.S. FDA Approval and Market..
25/4/202414:00GLOBEAquestive Therapeutics to Report First Quarter 2024..
12/4/202422:01GLOBEAquestive Therapeutics to Present Crossover Study Data for..
01/4/202414:00GLOBEAquestive Therapeutics Strengthens Board of Directors with..
25/3/202413:00GLOBEAquestive Therapeutics Announces Closing of Underwritten..
20/3/202402:49GLOBEAquestive Therapeutics Announces Pricing of $75 Million..
19/3/202421:01GLOBEAquestive Therapeutics Announces Proposed Public Offering of..
14/3/202422:23GLOBEAquestive Therapeutics Announces Pivotal Study for Anaphylm™..
11/3/202415:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202415:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202415:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202422:14EDGAR2Form 144 - Report of proposed sale of securities
05/3/202423:12EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
05/3/202423:09EDGAR2Form 8-K - Current report
05/3/202423:05GLOBEAquestive Therapeutics Reports Full Year 2023 Financial..
21/2/202414:00GLOBEAquestive Therapeutics to Report Fourth Quarter 2023..
15/2/202414:00GLOBEAquestive Therapeutics to Present Anaphylm™ (epinephrine)..
14/2/202421:24EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/2/202423:02EDGAR2Form S-8 - Securities to be offered to employees in employee..
30/1/202414:00GLOBEAquestive Therapeutics to Participate in Oppenheimer 34th..
08/12/202316:46EDGAR2Form 8-K - Current report
05/12/202314:51EDGAR2Form 8-K - Current report
05/12/202314:00GLOBEAquestive Therapeutics Doses First Patient in Phase 3..
10/11/202314:00GLOBEAquestive Therapeutics to Present Positive Data from..
08/11/202323:04EDGAR2Form 8-K - Current report
06/11/202323:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202323:20EDGAR2Form 8-K - Current report
06/11/202322:37GLOBEAquestive Therapeutics Reports Third Quarter 2023 Financial..
02/11/202313:45EDGAR2Form 8-K - Current report
02/11/202313:00GLOBEAquestive Therapeutics Completes $45 Million Debt..
31/10/202313:00GLOBEAquestive Therapeutics to Report Third Quarter 2023..
10/10/202318:04EDGAR2Form 8-K - Current report
09/10/202314:00GLOBEAquestive Therapeutics Provides Business Update
02/10/202322:18EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
02/10/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
20/9/202322:39EDGAR2Form 8-K - Current report
20/9/202316:57DJNAquestive Therapeutics Shares Rise 12% on Anaphylm Trial..
20/9/202315:04GLOBEAquestive Therapeutics Reaffirms Timeline and Pathway for..
11/9/202314:00GLOBEAquestive Therapeutics Receives FDA Acceptance of New Drug..
23/8/202314:00GLOBEAquestive Therapeutics to Participate in Two Upcoming..
11/8/202319:14EDGAR2Form 8-K - Current report
09/8/202323:22EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/8/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 3,40 Min: 3,205 Max: 3,4099
Chiusura: 3,365

La tua Cronologia

NASDAQ
AQST
Aquestive Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network